PT  - JOURNAL ARTICLE
AU  - Allison Bethanne Reiss
AU  - Amy D Glass
AU  - Thomas Wisniewski
AU  - Benjamin Wolozin
AU  - Irving H Gomolin
AU  - Aaron Pinkhasov
AU  - Joshua De Leon
AU  - Mark M Stecker
TI  - Alzheimer’s disease: many failed trials, so where do we go from here?
AID  - 10.1136/jim-2020-001297
DP  - 2020 Aug 01
TA  - Journal of Investigative Medicine
PG  - 1135--1140
VI  - 68
IP  - 6
4099  - http://hw-f5-jim.highwire.org/content/68/6/1135.short
4100  - http://hw-f5-jim.highwire.org/content/68/6/1135.full
SO  - J Investig Med2020 Aug 01; 68
AB  - Alzheimer’s disease (AD) is a neurodegenerative brain disorder associated with relentlessly progressive cognitive impairment and memory loss. AD pathology proceeds for decades before cognitive deficits become clinically apparent, opening a window for preventative therapy. Imbalance of clearance and buildup of amyloid β and phosphorylated tau proteins in the central nervous system is believed to contribute to AD pathogenesis. However, multiple clinical trials of treatments aimed at averting accumulation of these proteins have yielded little success, and there is still no disease-modifying intervention. Here, we discuss current knowledge of AD pathology and treatment with an emphasis on emerging biomarkers and treatment strategies.